Stockscreener 앱 받기
17.78
2.63%
-0.48
시간 외 거래:
17.44
-0.34
-1.91%
전일 마감가:
$18.26
열려 있는:
$18.43
하루 거래량:
386.77K
Relative Volume:
0.97
시가총액:
$970.13M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+4.34%
1개월 성능:
+49.04%
6개월 성능:
+75.17%
1년 성능:
-6.42%
1일 변동 폭
$17.49
$18.43
1주일 범위
$16.69
$18.49
52주 변동 폭
$7.80
$28.09
Bicara Therapeutics Inc Stock (BCAX) Company Profile
명칭
Bicara Therapeutics Inc
전화
617-468-4219
주소
116 HUNTINGTON AVENUE SUITE 703, BOSTON
BCAX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
17.78 | 997.22M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-05-23 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2025-04-17 | 개시 | Wells Fargo | Underweight |
| 2025-02-06 | 개시 | Wedbush | Outperform |
| 2024-12-06 | 개시 | H.C. Wainwright | Buy |
| 2024-11-05 | 개시 | Rodman & Renshaw | Buy |
| 2024-10-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-08 | 개시 | Morgan Stanley | Overweight |
| 2024-10-08 | 개시 | Stifel | Buy |
| 2024-10-08 | 개시 | TD Cowen | Buy |
모두보기
Bicara Therapeutics Inc 주식(BCAX)의 최신 뉴스
Bicara Therapeutics (NASDAQ:BCAX) CFO Ivan Hyep Sells 18,244 Shares - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) COO Sells $715,176.00 in Stock - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) COO Ryan Cohlhepp Sells 10,900 Shares - MarketBeat
Ivan Hyep Sells 6,514 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock - MarketBeat
Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) CFO Sells 5,627 Shares of Stock - MarketBeat
Risk adjusted return profile for Bicara Therapeutics Inc. analyzedJuly 2025 Selloffs & Breakout Confirmation Trade Signals - newser.com
Can Bicara Therapeutics Inc. stock resist sector downturnsWeekly Stock Report & Risk Managed Investment Strategies - newser.com
Bicara Therapeutics CFO Hyep Ivan sells $553,198 in shares By Investing.com - Investing.com South Africa
Bicara therapeutics president Cohlhepp sells $911k in shares - Investing.com
Bicara Therapeutics CFO Hyep Ivan sells $553,198 in shares - Investing.com
Day 8 of Gains Streak for Bicara Therapeutics Stock with 70% Return (vs. 4.3% YTD) [10/7/2025] - Trefis
4 Biotech Stocks Seeing Explosive Momentum GainsAldeyra Therapeutics (NASDAQ:ALDX) - Benzinga
Statistical indicators supporting Bicara Therapeutics Inc.’s strengthGlobal Markets & Expert Curated Trade Setup Alerts - newser.com
What drives Bicara Therapeutics Inc stock priceVWAP Trading Strategies & Free Tremendous Portfolio Expansion - earlytimes.in
Is Bicara Therapeutics Inc. stock reversal real or fakeJuly 2025 Trade Ideas & AI Powered Market Entry Ideas - newser.com
Key metrics from Bicara Therapeutics Inc.’s quarterly dataQuarterly Portfolio Summary & Weekly High Potential Alerts - newser.com
Bicara Therapeutics Files $400 Million Mixed Shelf - MarketScreener
Bicara Therapeutics files for mixed shelf offering of up to $400 millionSEC filing - MarketScreener
How to read the order book for Bicara Therapeutics Inc.Fed Meeting & Real-Time Sentiment Analysis - newser.com
Bicara reports positive Phase 1/1b trial results for cancer therapy - MSN
Stifel maintains Buy on Bicara stock with $47 target - MSN
Bicara Therapeutics stock rating reiterated as Buy by TD Cowen - Investing.com South Africa
Bicara Therapeutics stock rating reiterated as Buy by TD Cowen By Investing.com - Investing.com Nigeria
Bicara Therapeutics (NASDAQ:BCAX) Shares Up 5.5%Here's Why - MarketBeat
Promising Market Opportunity for Bicara Therapeutics in HPV-Negative Head & Neck Cancer Warrants Buy Rating - TipRanks
Morgan Stanley Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $36 - 富途牛牛
What analysts say about Bicara Therapeutics Inc stockTrend Following Strategies & Big Profit Small Investment - earlytimes.in
Brokerages Set Bicara Therapeutics Inc. (NASDAQ:BCAX) PT at $32.25 - Defense World
Optimistic Buy Rating for Bicara Therapeutics: Superior Clinical Benefits and Valuation Upside - TipRanks
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Average Rating of "Buy" from Analysts - MarketBeat
Bicara Therapeutics Inc (BCAX) 재무 분석
Bicara Therapeutics Inc (BCAX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Bicara Therapeutics Inc 주식 (BCAX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Raben David | Chief Medical Officer |
Oct 09 '25 |
Sale |
18.45 |
22,000 |
405,900 |
35,497 |
| Hyep Ivan | Chief Financial Officer |
Oct 09 '25 |
Option Exercise |
3.79 |
6,415 |
24,312 |
151,770 |
| Hyep Ivan | Chief Financial Officer |
Oct 09 '25 |
Sale |
18.23 |
6,415 |
116,931 |
145,355 |
5.74%
자본화:
|
볼륨(24시간):